FLT3 and acute myeloid leukemia: To better stratify AML patients into different risk groups, a survival scoring system incorporating TP53 mutation and nine other prognostic factors, including age, WBC counts, cytogenetics, NPM1/FLT3-ITD, CEBPA, IDH2, RUNX1, WT1 and DNMT3A mutations, into survival analysis was formulated.